Skip to main content

Peer Review reports

From: Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study

Original Submission
24 Aug 2023 Submitted Original manuscript
6 Oct 2023 Reviewed Reviewer Report
9 Oct 2023 Reviewed Reviewer Report
11 Oct 2023 Author responded Author comments - Chuansheng Zheng
Resubmission - Version 2
11 Oct 2023 Submitted Manuscript version 2
Publishing
16 Oct 2023 Editorially accepted
25 Oct 2023 Article published 10.1186/s12885-023-11535-5

You can find further information about peer review here.

Back to article page